TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Bullseye Asset Management LLC

Bullseye Asset Management LLC increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,754 shares of the company's stock after purchasing an additional 11,553 shares during the period. Bullseye Asset Management LLC owned 0.14% of TransMedics Group worth $2,977,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after acquiring an additional 40,860 shares during the last quarter. FIL Ltd lifted its position in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares during the last quarter. Geode Capital Management LLC lifted its position in TransMedics Group by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock valued at $48,191,000 after acquiring an additional 8,954 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of TransMedics Group by 83.3% in the fourth quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock worth $27,518,000 after buying an additional 200,603 shares during the last quarter. Finally, Emerald Advisers LLC raised its holdings in shares of TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after buying an additional 220,804 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMDX. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $105.00 price target (up previously from $90.00) on shares of TransMedics Group in a report on Tuesday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus target price of $124.20.

TransMedics Group Stock Performance

Shares of TransMedics Group stock traded down $1.28 during trading on Wednesday, hitting $91.15. 361,583 shares of the company's stock were exchanged, compared to its average volume of 1,347,155. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business has a 50-day simple moving average of $75.01 and a 200-day simple moving average of $77.21. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of 96.97 and a beta of 2.14.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.